Which has stronger earnings & valuation, RZLT or SEPN?

Septerna has higher revenue and earnings than Rezolute. Septerna is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Septerna $98.88M 18.18 -$48.88M -$0.54 N/A

Is RZLT or SEPN more profitable?

Rezolute has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Septerna -24.51% -9.57% -6.28%

Does the media prefer RZLT or SEPN?

In the previous week, Rezolute had 5 more articles in the media than Septerna. MarketBeat recorded 10 mentions for Rezolute and 5 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Rezolute's score of 0.30 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ANAB or RZLT?

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 6.80 -$13.23M -$1.08 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is ANAB or RZLT more profitable?

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% Rezolute N/A -58.82% -54.48%

Does the media favor ANAB or RZLT?

In the previous week, Rezolute had 4 more articles in the media than AnaptysBio. MarketBeat recorded 10 mentions for Rezolute and 6 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.54 beat Rezolute's score of 0.30 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rezolute 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NVAX or RZLT?

Novavax has higher revenue and earnings than Rezolute. Novavax is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 3.75 $440.30M -$1.52 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is NVAX or RZLT more profitable?

Rezolute has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Rezolute N/A -58.82% -54.48%

Does the media refer more to NVAX or RZLT?

In the previous week, Novavax had 3 more articles in the media than Rezolute. MarketBeat recorded 13 mentions for Novavax and 10 mentions for Rezolute. Novavax's average media sentiment score of 0.62 beat Rezolute's score of 0.30 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rezolute 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, TYRA or RZLT?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is TYRA or RZLT more profitable?

Tyra Biosciences' return on equity of -46.39% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -46.39% -43.07% Rezolute N/A -58.82% -54.48%

Does the media refer more to TYRA or RZLT?

In the previous week, Tyra Biosciences had 19 more articles in the media than Rezolute. MarketBeat recorded 29 mentions for Tyra Biosciences and 10 mentions for Rezolute. Rezolute's average media sentiment score of 0.30 beat Tyra Biosciences' score of 0.12 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral Rezolute 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, AAPG or RZLT?

Rezolute has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $642.64M 2.34 -$177.71M N/A N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is AAPG or RZLT more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Rezolute N/A -58.82% -54.48%

Rezolute (RZLT) Competitors

$4.22 +0.05 (+1.20%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.22 0.00 (-0.12%)

As of 09/11/2026 07:43 PM Eastern

Compare

RZLT vs. SEPN, ANAB, NVAX, TYRA, and AAPG

Should you buy Rezolute stock or one of its competitors? Rezolute's main competitors and comparable companies include Septerna (SEPN), AnaptysBio (ANAB), Novavax (NVAX), Tyra Biosciences (TYRA), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rezolute compare to Septerna?

Rezolute (NASDAQ:RZLT) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Septerna has higher revenue and earnings than Rezolute. Septerna is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Septerna	$98.88M	18.18	-$48.88M	-$0.54	N/A

Rezolute currently has a consensus price target of $9.38, indicating a potential upside of 122.16%. Septerna has a consensus price target of $52.44, indicating a potential upside of 36.18%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Rezolute had 5 more articles in the media than Septerna. MarketBeat recorded 10 mentions for Rezolute and 5 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Rezolute's score of 0.30 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Septerna	-24.51%	-9.57%	-6.28%

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 5.8% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rezolute has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Septerna has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

Summary

Septerna beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Rezolute	N/A	-58.82%	-54.48%

83.0% of Rezolute shares are held by institutional investors. 31.5% of AnaptysBio shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AnaptysBio has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

AnaptysBio currently has a consensus target price of $79.85, suggesting a potential upside of 48.22%. Rezolute has a consensus target price of $9.38, suggesting a potential upside of 122.16%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.80	-$13.23M	-$1.08	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

In the previous week, Rezolute had 4 more articles in the media than AnaptysBio. MarketBeat recorded 10 mentions for Rezolute and 6 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.54 beat Rezolute's score of 0.30 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rezolute	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AnaptysBio beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Novavax?

Novavax (NASDAQ:NVAX) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Novavax has higher revenue and earnings than Rezolute. Novavax is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	3.75	$440.30M	-$1.52	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, Novavax had 3 more articles in the media than Rezolute. MarketBeat recorded 13 mentions for Novavax and 10 mentions for Rezolute. Novavax's average media sentiment score of 0.62 beat Rezolute's score of 0.30 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rezolute	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 48.62%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 122.16%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Rezolute has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Rezolute	N/A	-58.82%	-54.48%

53.0% of Novavax shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rezolute beats Novavax on 8 of the 15 factors compared between the two stocks.

How does Rezolute compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Tyra Biosciences has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Tyra Biosciences' return on equity of -46.39% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Rezolute	N/A	-58.82%	-54.48%

Tyra Biosciences is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tyra Biosciences presently has a consensus target price of $47.88, indicating a potential upside of 117.32%. Rezolute has a consensus target price of $9.38, indicating a potential upside of 122.16%. Given Rezolute's higher probable upside, analysts plainly believe Rezolute is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Tyra Biosciences had 19 more articles in the media than Rezolute. MarketBeat recorded 29 mentions for Tyra Biosciences and 10 mentions for Rezolute. Rezolute's average media sentiment score of 0.30 beat Tyra Biosciences' score of 0.12 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tyra Biosciences beats Rezolute on 7 of the 13 factors compared between the two stocks.

How does Rezolute compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Rezolute has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$642.64M	2.34	-$177.71M	N/A	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

In the previous week, Rezolute had 8 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 10 mentions for Rezolute and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.45 beat Rezolute's score of 0.30 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Rezolute	N/A	-58.82%	-54.48%

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 188.38%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 122.16%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities analysts plainly believe Ascentage Pharma Group International is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Ascentage Pharma Group International beats Rezolute on 7 of the 12 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$401.54M	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-5.15	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	2.27	15.12	10.33	6.20
Net Income	-$74.41M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.86%	-4.34%	-3.32%	-2.35%
1 Month Performance	-10.21%	-0.02%	-0.41%	-2.77%
1 Year Performance	-45.12%	40.64%	19.21%	7.63%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.3504 of 5 stars	$4.22 +1.2%	$9.38 +122.2%	-47.1%	$401.54M	N/A	N/A	40	Upcoming Earnings
SEPN Septerna	3.2474 of 5 stars	$36.48 -0.7%	$52.44 +43.8%	+167.1%	$1.70B	$45.95M	N/A	N/A	Positive News
ANAB AnaptysBio	2.8358 of 5 stars	$55.78 -1.8%	$79.85 +43.1%	+132.2%	$1.67B	$234.60M	N/A	100	Positive News Upcoming Earnings
NVAX Novavax	2.0972 of 5 stars	$9.86 -3.5%	$14.00 +42.0%	+13.8%	$1.66B	$1.12B	N/A	1,990	Trending News Analyst Upgrade
TYRA Tyra Biosciences	3.1354 of 5 stars	$28.08 -2.0%	$48.22 +71.7%	+76.7%	$1.65B	N/A	N/A	20	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors